All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.
The Lymphoma Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy
Introducing
Now you can personalise
your Lymphoma Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for you
Find out moreThe Lymphoma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Lymphoma Hub cannot guarantee the accuracy of translated content. The Lymphoma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The Lymphoma & CLL Hub is an independent medical education platform, sponsored by Beigene and Roche, and supported through educational grants from Bristol Myers Squibb, Ipsen Biopharmaceuticals, Lilly, Pfizer, and Pharmacyclics LLC, an AbbVie Company and Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC View funders.
ASH 2018 | Practice changing abstracts in non-Hodgkin lymphoma and chronic lymphocytic leukemia
Bookmark this article
Did you miss ASH 2018? The Lymphoma Hub attended the 60th ASH Annual Meeting & Exposition, December 1–4 2018, San Diego, CA and has developed a downloadable resource, which provides information on the practice changing abstracts across lymphoma and CLL.
Our selection of ASH 2018 abstracts include comments from The Lymphoma Hub Steering Committee members Stefano Luminari and Gilles Salles on ibrutinib combination therapies for the front-line treatment of CLL, and the role of the lenalidomide and rituximab combination in relapsed follicular lymphoma. Hear from the experts on the role of mutations that confer resistance to venetoclax and whether less is more when it comes to front line treatment in patients with DLBCL.
ASH 2018 | Practice changing abstracts in non-Hodgkin lymphoma and chronic lymphocytic leukemia
If you would like to view the ASH 2018 highlights, practice changing abstracts and expert opinions please find the Lymphoma Hub resource below:
Download Here- #LBA-4: A randomized phase III study of ibrutinib (PCI-32765)-based therapy vs. standard fludarabine, cyclophosphamide, and rituximab (FCR) chemoimmunotherapy in untreated younger patients with chronic lymphocytic leukemia (CLL): a trial of the ECOG-ACRIN cancer research group (E1912).
https://lymphomahub.com/medical-information/ash-2018-ibrutinib-plus-rituximabprovide-superior-outcomes-than-fcr-in-naive-cll-patients-results-from-the-ecog-acrinphase-iii-trial-e1912 - #LBA-7: Acquisition of the recurrent Gly101Val mutation in BCL2 confers resistance to venetoclax in patients with progressive chronic lymphocytic leukemia.
https://lymphomahub.com/medical-information/novel-bcl2-mutation-leads-to-venetoclaxresistance-in-progressive-cll-patients - #691: Ibrutinib + obinutuzumab versus chlorambucil + obinutuzumab as first-line treatment in patients with chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL): results from phase 3 iLLUMINATE.
https://lymphomahub.com/medical-information/ash-2018-results-from-the-phase-iiiilluminate-trial-on-chemotherapy-free-first-line-treatment-for-cll-sll - #781: Excellent outcome of young patients (18-60 years) with favorable-prognosis diffuse large B-Cell lymphoma (DLBCL) treated with 4 cycles CHOP plus 6 applications of rituximab: results of the 592 patients of the Flyer trial of the Dshnhl/GLA.
https://lymphomahub.com/medical-information/ash-2018-results-from-the-flyer-trial-on-the-efficacy-offour-r-chop-cycles-versus-six-in-young-nhl-patients - #783: No added benefit of eight versus six cycles of CHOP when combined with rituximab in previously untreated diffuse large B-Cell lymphoma patients: results from the international phase III GOYA study.
https://lymphomahub.com/medical-information/ash-2018-results-from-the-phase-iii-goya-trial-r-chopversus-g-chop-for-first-line-dlbcl - #997: The ECHELON-2 trial: results of a randomized, double-blind, active-controlled phase 3 study of brentuximab vedotin and CHP (A+CHP) versus CHOP in the frontline treatment of patients with CD30+ peripheral T-cell lymphomas.
https://lymphomahub.com/medical-information/brentuximab-vedotin-plus-chemotherapy-for-cd30-ptcl-results-from-the-phase-iii-echelon-2-trial - #445: AUGMENT: A phase III randomized study of lenalidomide plus rituximab (R2) vs rituximab/placebo in patients with relapsed/refractory indolent non-Hodgkin lymphoma.
https://lymphomahub.com/medical-information/ash-2018-results-from-the-phase-iii-augmenttrial-lenalidome-plus-rituximab-for-r-r-fl-and-mzl
https://lymphomahub.com/medical-information/nathan-fowler-ash-2018-long-term-updates-onlenalidomide-plus-rituximab-in-fl
Understanding your specialty helps us to deliver the most relevant and engaging content.
Please spare a moment to share yours.
Please select or type your specialty
Thank youYour opinion matters
44 votes - 79 days left ...
Related articles
Newsletter
Subscribe to get the best content related to lymphoma & CLL delivered to your inbox